Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,117 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07272200Recruiting
Genes and alcohol in liver cancer: a study
This study looks at how your genes and alcohol use together affect the risk of liver cancer. It may help find ways to prevent cancer in people with fatty liver disease or moderate alcohol intake.
Milan, MilanoAges 45–75 - NCT06893861Recruiting
Testing a new blood test for endometrial cancer screening
This study is testing whether a blood test that looks at small molecules (metabolites) can help find endometrial cancer early in post-menopausal women. If you are between 50 and 80 years old and have not had a hysterectomy or certain hormone treatments, you may be able to join.
NaplesAges 50–80 - NCT07264075RecruitingPhase 3
Ivonescimab with or without ligufalimab vs pembrolizumab for head and neck cancer
This trial tests a new immunotherapy combination (ivonescimab alone or with ligufalimab) against the standard immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread. It may be an option if you have not had any prior immunotherapy and your tumor is PD-L1 positive.
Le HavreAges 18–80 - NCT07266480RecruitingPhase 2
Adalimumab after surgery for esophageal cancer
This trial tests whether adding adalimumab (a medicine that helps the immune system) after surgery can prevent esophageal cancer from coming back. It's for people who have already had their cancer completely removed by surgery.
Shijiazhuang, HebeiAges 18 years+ - NCT07266363Recruiting
Blood test for early detection of esophageal cancer
This study is testing a blood test to detect esophageal squamous cell cancer early. Researchers are looking for a pattern of molecules in the blood that could signal the presence of this cancer.
Monrovia, CaliforniaAges 18 years+ - NCT07267806RecruitingPhase 3
Camrelizumab and Apatinib with or without chemo for advanced liver cancer
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
Guangzhou, GuangdongAges 18 years+ - NCT06693323RecruitingPhase 2
AHCC supplement with standard therapy for HPV-related head and neck cancer
This trial tests whether adding an AHCC supplement to standard treatment can improve outcomes for people with HPV-positive head and neck cancer. It is for patients who have had surgery and have certain high-risk features, like positive margins or cancer spread to lymph nodes.
Orange, CaliforniaAges 18–79 - NCT06899789Recruiting
Long-term follow-up of colitis from checkpoint inhibitors
This study follows people who developed colitis (inflammation in the colon) after receiving immune checkpoint inhibitors for cancer. Researchers want to learn about long-term effects and outcomes.
Pavia, PaviaAges 18 years+ - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+ - NCT07259317RecruitingPhase 2
Relacorilant plus chemo for metastatic pancreatic cancer
This trial tests adding a drug called relacorilant to standard chemotherapy (nab-paclitaxel and gemcitabine) for people with pancreatic cancer that has spread. The goal is to see if this combination works better than chemo alone.
Scottsdale, ArizonaAges 18 years+ - NCT07257094Recruiting
French questionnaire study for nose reconstruction after skin cancer
This study is testing a new French questionnaire to measure how satisfied people are with their nose reconstruction after skin cancer removal. It will help doctors better understand what matters most to patients after this type of surgery.
CaenAges 18 years+ - NCT07258186Recruiting
Endometrial cancer organoid study
This study creates miniature 3D versions of endometrial cancer tumors (organoids) from tissue samples taken during surgery. The goal is to better understand the disease and find personalized treatments.
Roma, RomaAges 18 years+ - NCT06536439Recruiting
Digital tool to plan kidney clamping during robotic surgery
This trial tests a new digital tool that helps surgeons plan the best way to clamp the blood supply to your kidney during robotic surgery. The tool aims to reduce damage to healthy kidney tissue while still blocking the tumor's blood flow.
AalstAges 18 years+ - NCT06905262Recruiting
Finding cancer targets for liver cancer immunotherapy
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
NaplesAges 18–100 - NCT07249112Recruiting
Genomic study of metabolic fatty liver disease
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
Milan, MilanoAges 18–90 - NCT07242417RecruitingEarly Phase 1
TC-G203 for adults with GPC3-positive advanced solid tumors
This trial tests an experimental cell therapy (TC-G203) for people with advanced solid tumors that have a specific protein called GPC3. It aims to see if this treatment is safe and effective for those who haven't responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07242859Recruiting
Rice bran for mouth sores from radiation in head and neck cancer
This trial tests whether a rice bran supplement can help prevent or reduce mouth sores caused by radiation therapy for head and neck cancer. If you're getting radiation with or without chemo, this simple addition might ease side effects.
CairoAges 18 years+ - NCT07240610Recruiting
Radiation and immunotherapy for kidney cancer that has spread
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
Chūō, YamanashiAges 18 years+ - NCT07242547RecruitingPhase 2
Tarlatamab maintenance for limited-stage small cell lung cancer
This trial tests a new immunotherapy medicine called tarlatamab given as maintenance therapy after initial treatment for limited-stage small cell lung cancer. It aims to keep the cancer from coming back.
Albacete, AlbaceteAges 18 years+ - NCT05290038Recruiting
Review study for adults with metastatic UC treated with specific drugs
This is a study that looks back at past medical records of adults with metastatic urinary tract cancer. It specifically includes people who received certain immunotherapy or antibody-drug treatments during set time periods, to help researchers understand outcomes and care patterns.
Province of Macerata, MacerataAges 18 years+ - NCT04462042Recruiting
Proton vs photon radiation for anal canal cancer
This study compares two types of radiation—protons versus photons—for anal canal squamous cell carcinoma. It may help find which option delivers treatment more effectively or with fewer side effects.
GothenburgAges 18 years+ - NCT04464122Recruiting
Testing blood markers to diagnose and gauge early response in NEN
This trial studies whether specific blood “biomarkers” can help confirm a type of cancer called NEN (neuroendocrine neoplasm) and show whether treatment is working early. It may help doctors start or adjust treatment sooner, especially for cancers that are advanced or have spread.
Rome, ItalyAges 18–80 - NCT07239596RecruitingPhase 1/Phase 2
Study of three drugs for advanced kidney cancer
This trial tests a combination of three drugs (SHR-8068, adebrelimab, and another anti-tumor drug) for people with advanced kidney cancer (clear cell type). The goal is to see if the combination works better than current treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07230691Recruiting
Study of amivantamab for advanced EGFR-mutated lung cancer
This study looks at how well a treatment called amivantamab works in people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). It aims to track real-world outcomes in patients who are starting amivantamab for the first time.
GrazAges 18 years+
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,117 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.